Analystreport

Reata Pharmaceuticals Inc (NASDAQ: RETA) had its price target lowered by analysts at Stifel Nicolaus from $280.00 to $225.00. They now have a "buy" rating on the stock.

Reata Pharmaceuticals, Inc. - Class A  (RETA) 
Last reata pharmaceuticals, inc. - class a earnings: 2/19 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.reatapharma.com